NCT05988372 2023-11-01Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)Sun Yat-sen UniversityPhase 2 Not yet recruiting50 enrolled